Physician profile
Violet E Thomas
NPI 1376386946
$4,980.46
in general payments reported to CMS, 2019-2025
21 companies · $3,782 in 2025
The $3,782 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,198 · 2025: $3,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.46 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,420.26 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $403.76 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $379.89 | 2024-2025 | Glassia, Cuvitru, Takhzyro |
| Grifols USA, LLC | $320.11 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $277.88 | 2024-2025 | |
| Pharming Healthcare, INC. | $258.88 | 2024-2025 | Ruconest |
| Genentech USA, INC. | $258.57 | 2024-2025 | Xolair |
| Csl Behring | $245.91 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Novartis Pharmaceuticals Corporation | $239.54 | 2025 | |
| Glaxosmithkline, LLC. | $229.01 | 2025 | Nucala, Trelegy Ellipta |
| Octapharma USA, INC. | $204.15 | 2024-2025 | Panzyga |
| Pfizer INC. | $166.41 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $160.18 | 2024-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $92.77 | 2025 | Nemluvio |
| Amgen INC. | $91.92 | 2024-2025 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $66.48 | 2025 | Inspire |
| Cycle Pharmaceuticals INC | $46.92 | 2025 | Sajazir |
| Blueprint Medicines Corporation | $42.87 | 2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $40.95 | 2025 | Neffy |
| Organon LLC | $17.34 | 2025 | Vtama |
| Dermavant Sciences, INC. | $16.66 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violet Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.